文献速递精神分裂症与精神病性障碍

miR143-3p介导的NRG-1依赖性线粒体功能障碍参与难治性精神分裂症奥氮平耐药

miR143-3p-Mediated NRG-1-Dependent Mitochondrial Dysfunction Contributes to Olanzapine Resistance in Refractory Schizophrenia.
PubMed 文献 · Biol Psychiatry · 2022-03-26

该研究通过RNA测序分析3例奥氮平应答者和4例无应答者的诱导多能干细胞来源神经干细胞,发现NRG-1缺陷诱导的线粒体功能障碍与奥氮平治疗结局相关。NRG-1敲除小鼠表现出精神分裂症相关行为缺陷和奥氮平耐药,而miR143-3p agomir脑内注射可逆转耐药。

要点

  • NRG-1缺陷诱导的线粒体功能障碍与TRS患者奥氮平治疗结局相关。
  • NRG-1敲除小鼠表现出精神分裂症相关行为缺陷和奥氮平耐药。
  • miR143-3p agomir脑内注射可逆转NRG-1敲除小鼠的奥氮平耐药。

核心结论

  • 奥氮平耐药源于NRG-1缺陷诱导的线粒体功能障碍,NRG-1/miR143-3p轴构成TRS的新型生物标志物和治疗靶点。

研究设计与样本

  • 对3例奥氮平应答者(PANSS评分减分率≥25%)和4例无应答者(PANSS评分减分率<25%)的TRS住院患者,用诱导多能干细胞来源神经干细胞进行无偏RNA测序。
  • 对TRS患者进行基因分型研究以评估与奥氮平反应相关的候选基因。
  • 使用CRISPR/Cas9基因组编辑、神经行为学测试、RNA沉默和microRNA测序研究奥氮平耐药基因的表型机制。

主要发现

  • NRG-1缺陷诱导的线粒体功能障碍与TRS中奥氮平治疗结局相关。
  • NRG-1敲除小鼠表现出精神分裂症相关行为缺陷并产生奥氮平耐药。
  • miR143-3p是NRG-1下游与线粒体功能障碍相关的关键靶点,神经干细胞中miR143-3p水平与TRS奥氮平耐药严重程度相关。
  • NRG-1敲除小鼠的奥氮平耐药可通过脑内注射miR143-3p agomir逆转。

关键数值与推荐

  • 奥氮平应答定义为PANSS评分减分率≥25%,无应答定义为PANSS评分减分率<25%。

临床怎么用

  • NRG-1/miR143-3p轴可能作为TRS奥氮平耐药的生物标志物和治疗靶点。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Olanzapine is an effective antipsychotic medication for treatment-resistant schizophrenia (TRS); however, the therapeutic effectiveness of olanzapine has been found to vary in individual patients. It is imperative to unravel its resistance mechanisms and find reliable targets to develop novel precise therapeutic strategies. METHODS: Unbiased RNA sequencing analysis was performed using homogeneous populations of neural stem cells derived from induced pluripotent stem cells in 3 olanzapine responder (reduction of Positive and Negative Syndrome Scale score ≥25%) and 4 nonresponder (reduction of Positive and Negative Syndrome Scale score <25%) inpatients with TRS. We also used a genotyping study from patients with TRS to assess the candidate genes associated with the olanzapine response. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9-mediated genome editing, neurologic behavioral tests, RNA silencing, and microRNA sequencing were used to investigate the phenotypic mechanisms of an olanzapine resistance gene in patients with TRS. RESULTS: Neuregulin-1 (NRG-1) deficiency-induced mitochondrial dysfunction is associated with olanzapine treatment outcomes in TRS. NRG-1 knockout mice showed schizophrenia-relevant behavioral deficits and yielded olanzapine resistance. Notably, miR143-3p is a critical NRG-1 target related to mitochondrial dysfunction, and miR143-3p levels in neural stem cells associate with severity to olanzapine resistance in TRS. Meanwhile, olanzapine resistance in NRG-1 knockout mice could be rescued by treatment with miR143-3p agomir via intracerebral injection. CONCLUSIONS: Our findings provide direct evidence of olanzapine resistance resulting from NRG-1 deficiency-induced mitochondrial dysfunction, and they link olanzapine resistance and NRG-1 deficiency-induced mitochondrial dysfunction to an NRG-1/miR143-3p axis, which constitutes a novel biomarker and target for TRS.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Sun J, Zhang X, Cong Q, et al. miR143-3p-Mediated NRG-1-Dependent Mitochondrial Dysfunction Contributes to Olanzapine Resistance in Refractory Schizophrenia. Biol Psychiatry. 2022. PMID: 35662508. doi:10.1016/j.biopsych.2022.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。